Lusutrombopag

Drug Profile

Lusutrombopag

Alternative Names: MULPLETA; S-888711

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shionogi
  • Class Small molecules; Thiazoles
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombocytopenia
  • Discontinued Immune thrombocytopenic purpura

Most Recent Events

  • 01 Nov 2017 Shionogi completes a phase I/II trial in Thrombocytopenia in Japan (PO) (JapicCTI-163289)
  • 01 Nov 2017 Shionogi completes a phase III trial in Thrombocytopenia in Japan (PO) (JapicCTI-153023)
  • 20 Oct 2017 Updated efficacy and adverse events data from a phase III trial in Thrombocytopenia presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top